Phenotype News and Research

RSS

Regulus Therapeutics presents new data on oncology, immune disease and HCV therapeutic programs

Regulus Therapeutics Inc. today announced that new pre-clinical data from multiple therapeutic programs were presented at the “RNA Silencing: Mechanism, Biology and Application” Keystone Symposium held January 14 – 19, 2010 in Keystone, Colorado. Regulus and its collaborators presented data showing microRNA target regulation by anti-miRs, as well as data from therapeutic programs focused on oncology, immune disease and hepatitis C virus (HCV) infection.

18 Jan 2010

Work provides new insight into potential therapeutic treatments for cancer diseases

An enzyme that normally helps break down stored fats goes into overdrive in some cancer cells, making them more malignant, according to new findings by a team at The Scripps Research Institute.

13 Jan 2010

ESF-UB Conference to concentrate on potentially clinically relevant polymorphisms

Pharmacogenetics started in the fifties with the discovery of primaquine-related haemolysis among glucose-6-phosphate deshydrogenase deficient patients. At the end of the century, it progressively evolved into Pharmacogenomics, investigating simultaneously multiple gene targets till covering the whole genome in relation with altered drug response.

8 Jan 2010

New genetic findings may lead to better interventional therapies for obsessive compulsive disorders

A collaboration between the University of Massachusetts Medical School, the Cummings School of Veterinary Medicine at Tufts University and the Broad Institute at the Massachusetts Institute of Technology has identified a genetic locus on canine chromosome 7 which coincides with an increased risk of obsessive compulsive disorder (OCD) susceptibility.

7 Jan 2010

Author evaluates potential benefits of IAD for treating prostate cancer

'Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature' is the title of an article by P-A. Abrahamsson in the January issue of European Urology, the official journal of the European Association of Urology. The author evaluates available evidence regarding the efficacy and tolerability of intermittent androgen deprivation (IAD) and assess its value in the treatment of prostate cancer (PCa).

5 Jan 2010

Presence of Streptococcus pneumoniae could predict risk of severe disease in H1N1 pandemic influenza

The presence of the Streptococcus pneumoniae in samples that can be easily obtained in clinics and emergency rooms may predict risk of severe disease in H1N1 pandemic influenza.

31 Dec 2009

NHLBI grant for identifying genetic and epigenetic causes of human congenital heart disease

Researchers at Children's Hospital Boston and Brigham and Women's Hospital have received funding from the National Heart, Lung, and Blood Institute (NHLBI) to support their search for undiscovered gene defects that cause congenital heart disease. The $4.19 million, 6-year grant is part of the Pediatric Cardiac Genomics Consortium (PCGC), which seeks to identify genetic and epigenetic causes of human congenital heart disease, and relate genetic variants present in the congenital heart disease patient population to clinical outcomes.

23 Dec 2009

Scientists identify role of epigenetic changes in SLE

Identical twins look the same and are nearly genetically identical, but environmental factors and the resulting cellular changes could cause disease in one sibling and not the other.

22 Dec 2009

Landmark study provides new insight into congenital heart defects

Researchers from the UC San Diego, School of Medicine and colleagues have identified a new gene, ETS-1, that is linked to human congenital heart defects. The landmark study, recently published online in the journal of Human Molecular Genetics, provides important insights into some of the most prevalent forms of congenital heart defects in humans, including ventricular septal defects and potentially hypoplastic left heart syndrome, a uniformly fatal heart abnormality.

18 Dec 2009

Researchers present new data for diagnosis and management of beast cancer

As therapies for breast cancer continue to emerge, the issues of how to best monitor success and gauge prognosis remain important questions.

14 Dec 2009

Cytometry system to precisely control cell movement using sound waves

Applied Biosystems, part of Life Technologies Corporation today announced its entry into the flow cytometry instrumentation market with the debut of the Attune™ Acoustic Focusing Cytometer, a first of its kind cytometry system designed to use sound waves to precisely control the movement of cells.

7 Dec 2009

'Twist' gene plays a key role in the development of breast cancer

Working with mice, scientists at Johns Hopkins publishing in the December issue of Neoplasia have shown that a protein made by a gene called "Twist" may be the proverbial red flag that can accurately distinguish stem cells that drive aggressive, metastatic breast cancer from other breast cancer cells.

5 Dec 2009

People who smoke immediately after waking up face high risk of lung cancer

People who smoke their first cigarette within minutes after waking up have much higher levels of cotinine, a by-product of nicotine when processed by the body, than those who wait to smoke, regardless of the number of cigarettes smoked.

3 Dec 2009

Exiqon announces the recognition of ICCB-L

Exiqon A/S announced today that the Harvard Medical School ICCB-Longwood Screening Facility (ICCB-L) has been recognized as a MicroRNA Screening Center of Excellence.

30 Nov 2009

Comparison study finds no significant differences in post-transplant survival rates of NASH and ETOH groups

Researchers at the University of Miami School of Medicine compared the outcomes of cirrhotic patients who underwent liver transplants for nonalcoholic steatohepatitis (NASH) versus alcoholic liver disease (ETOH) and found no statistically significant differences in post-transplant survival rates between the NASH and ETOH groups

25 Nov 2009

NIGMS invests $42.3 million in "Grand Opportunities" grant

The National Institute of General Medical Sciences (NIGMS), part of the National Institutes of Health (NIH), is investing $42.3 million for grants in scientific areas it identified as "Grand Opportunities (GO)." NIH developed the GO grant program to stimulate biomedical research and the economy using funds provided by the American Recovery and Reinvestment Act (Recovery Act).

24 Nov 2009

Book on pediatric IBD launched

Chronic inflammatory bowel disease (IBD) encompasses Crohn's disease, ulcerative colitis and indeterminate colitis. The distinct phenotype in pediatric and adolescent patients and the difference from adult IBD make early-onset IBD a unique subgroup requiring specific therapeutic considerations. In this book, leading experts from the USA, Europe and Israel present new data on the genetics, epidemiology, pathology and pathogenesis of pediatric IBD. Imaging and endoscopy in the diagnosis of IBD are also discussed.

19 Nov 2009

Diagnosing patients with syndrome similar to neurofibromatosis type 1 may be difficult

An analysis of patients with a syndrome similar to the genetic disorder, neurofibromatosis type 1, indicates that diagnosis may be difficult because of shared clinical findings, such as certain pigmentary characteristics, according to a study in the November 18 issue of JAMA.

19 Nov 2009

New biomarkers can predict patients' response to certain drugs

Recent advances in cancer therapeutics have led to the discovery of biomarkers that can predict patient response to certain drugs. Screening for mutations in the epidermal growth factor receptor (EGRF) prior to non-small cell lung cancer treatment, for example, has been shown to indentify patients who are likely to respond to treatment with erlontinib. This maximizes the drug's impact, and spares patients who are not likely to benefit from being subjected to potentially debilitating side effects.

19 Nov 2009

Fully integrated human genome sequencing and data processing service launched

Knome, Inc., a recognized pioneer in the personal genomics field, today announced the launch of KnomeDISCOVERY, the first fully integrated human genome sequencing and data processing service for researchers. The new offering meets rapidly emerging demand from biomedical researchers for a one-stop service that bundles affordable, research-tailored access to a broad range of next-generation sequencing platforms with discovery-supportive data management and analysis.

18 Nov 2009

Phenotype News and Research

Regulus Therapeutics presents new data on oncology, immune disease and HCV therapeutic programs

Work provides new insight into potential therapeutic treatments for cancer diseases

ESF-UB Conference to concentrate on potentially clinically relevant polymorphisms

New genetic findings may lead to better interventional therapies for obsessive compulsive disorders

Author evaluates potential benefits of IAD for treating prostate cancer

Presence of Streptococcus pneumoniae could predict risk of severe disease in H1N1 pandemic influenza

NHLBI grant for identifying genetic and epigenetic causes of human congenital heart disease

Scientists identify role of epigenetic changes in SLE

Landmark study provides new insight into congenital heart defects

Researchers present new data for diagnosis and management of beast cancer

Cytometry system to precisely control cell movement using sound waves

'Twist' gene plays a key role in the development of breast cancer

People who smoke immediately after waking up face high risk of lung cancer

Exiqon announces the recognition of ICCB-L

Comparison study finds no significant differences in post-transplant survival rates of NASH and ETOH groups

NIGMS invests $42.3 million in "Grand Opportunities" grant

Book on pediatric IBD launched

Diagnosing patients with syndrome similar to neurofibromatosis type 1 may be difficult

New biomarkers can predict patients' response to certain drugs

Fully integrated human genome sequencing and data processing service launched

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News